Olumiant 4 mg contains baricitinib, a prescription medicine that reduces inflammation by inhibiting specific enzymes involved in immune system activity. Depending on local approval, it is used to treat conditions such as severe alopecia areata, rheumatoid arthritis, and atopic dermatitis.
Olumiant 4 mg is a branded medicine containing baricitinib, an oral JAK inhibitor. It works by reducing the activity of certain immune system pathways involved in inflammation.
Depending on the country and approved indication, baricitinib may be prescribed for adults with rheumatoid arthritis, severe alopecia areata, or atopic dermatitis. Its use requires medical supervision because it can increase the risk of serious infections and other complications.
Olumiant 4 mg may be prescribed to:
Treat severe alopecia areata, an autoimmune condition that causes hair loss.
Manage moderate to severe rheumatoid arthritis when previous treatments have not worked adequately or have not been tolerated.
Treat moderate to severe atopic dermatitis in eligible patients when other treatments are insufficient or unsuitable, where approved.
Approved uses and eligibility criteria vary by country. The appropriate treatment and dose must be determined by a specialist healthcare professional.
Baricitinib blocks Janus kinase (JAK) enzymes, which help transmit signals involved in immune responses and inflammation. By inhibiting these pathways, it can reduce inflammation affecting the joints, skin, or hair follicles, depending on the condition being treated.
The response develops over time and varies according to the condition and individual circumstances. Regular medical follow-up helps assess treatment effectiveness and monitor potential complications.
Take Olumiant 4 mg exactly as prescribed by your healthcare professional.
It is generally taken by mouth once daily, but the prescribed dose may differ according to the condition being treated, kidney function, age, and other risk factors.
Swallow the tablet with water. It can generally be taken with or without food.
Take it at a consistent time each day, following your prescription.
If you miss a dose, follow the instructions in the patient information leaflet or ask your pharmacist. Do not take a double dose to make up for a missed dose.
Do not stop treatment or change the dose without consulting your healthcare professional.
Your doctor may temporarily interrupt treatment if you develop a serious infection or certain blood test abnormalities.
Tell your doctor or pharmacist about your medical history and all medicines, supplements, and herbal products you use before starting Olumiant.
Important precautions include:
Infections: Baricitinib can increase the risk of serious infections, including tuberculosis and shingles. Screening for tuberculosis and other relevant infections may be required before treatment.
Blood clots: Treatment may increase the risk of blood clots in the veins or arteries. Tell your doctor if you have a history of thrombosis or risk factors for blood clots.
Heart disease and stroke: People with cardiovascular disease or relevant risk factors may require additional assessment.
Cancer: Malignancies have been reported with JAK inhibitors. Your doctor should assess individual risk factors before treatment.
Kidney or liver problems: These conditions may affect treatment suitability or the prescribed dose.
Blood cell abnormalities: Blood tests are required to monitor blood counts and other laboratory parameters.
Vaccinations: Live vaccines are generally not recommended during treatment. Discuss planned vaccinations with your healthcare professional.
Important interactions include other JAK inhibitors, biologic immunomodulators, potent immunosuppressants, and medicines such as probenecid that can affect baricitinib exposure. Certain combinations may increase the risk of infection or other adverse effects.
Seek urgent medical attention for sudden chest pain, difficulty breathing, one-sided leg swelling, or sudden weakness or difficulty speaking. Check all possible interactions and precautions with your doctor or pharmacist before starting or stopping any medicine.
Olumiant may cause harm to an unborn baby based on animal studies and should not be used during pregnancy under current European product guidance. People who could become pregnant should discuss effective contraception with their healthcare professional; European guidance recommends contraception during treatment and for at least one week after the last dose.
Breastfeeding is not recommended during treatment under the cited prescribing guidance. Recommendations and the advised period after the last dose may vary by country, so consult your doctor before using Olumiant if you are pregnant, planning a pregnancy, or breastfeeding.
Like all medicines, Olumiant can cause side effects, although not everyone experiences them.
Common or recognised side effects include:
Upper respiratory tract infections, such as nose and throat infections
Headache
Increased cholesterol levels
Urinary tract infections
Cold sores or shingles
Nausea or acne, depending on the condition being treated
Seek prompt medical attention for signs of a serious infection, severe abdominal pain, unexplained fever, or symptoms that may indicate a blood clot, such as sudden chest pain, breathing difficulty, or painful swelling in one leg. Sudden neurological symptoms also require emergency assessment.
This is not a complete list of side effects or warnings. Please refer to the product packaging and patient information leaflet supplied with your medicine for complete information and speak with your doctor or pharmacist if you have concerns.
Store Olumiant 4 mg according to the instructions shown on the original product packaging.
Keep the tablets in their original packaging.
Protect the medicine from excessive heat and moisture.
Keep it out of reach of children.
Do not use the tablets after their expiry date.
Follow the storage instructions supplied with your specific product, as requirements may vary by market.
Olumiant contains baricitinib, which is used for certain inflammatory and autoimmune conditions, including severe alopecia areata and rheumatoid arthritis. It is also approved for atopic dermatitis in eligible patients in some countries.
The time to notice improvement varies by condition and individual response. Your healthcare professional will monitor your progress and determine whether treatment is working as expected.
Olumiant tablets can generally be taken with or without food. Follow the instructions provided with your specific product.
Olumiant is the brand name, and baricitinib is its active ingredient. Other baricitinib products may be available in some markets, but product availability and approval status vary by country.
Baricitinib is approved for severe alopecia areata in certain age groups and may help hair regrowth in eligible patients. The degree of response and the time needed to see improvement vary.
Do not stop taking Olumiant without consulting your healthcare professional. Your doctor will determine the appropriate duration of treatment and whether any dose changes are needed.
Yes. Blood tests are generally needed before and during treatment to monitor blood counts, cholesterol, liver-related parameters, and other relevant measures. Your healthcare professional will determine the appropriate monitoring schedule.
